Novo, a life science investor, completed the acquisition of Altasciences, a fully-integrated, early drug development services platform, from private equity firm Audax. Financial terms were not disclosed. "This is an exciting day for Altasciences. We are very pleased to be partnering with Novo Holdings in the next phase of our exciting journey, given their exceptional reputation, track record, and broad portfolio of high-growth healthcare companies. We look forward to continuing our ambitious growth plans and commitment to providing clients with value-added services that offer a new paradigm of drug development outsourcing," Chris Perkin, Altasciences CEO.